PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3978623-3	1985	All four inhibitors of aldehyde dehydrogenase activity potentiated the cytotoxic action of the oxazaphosphorines, 4-hydroperoxycyclophosphamide and ASTA Z-7557, against L1210/OAP and P388/CLA cells; in the presence of a sufficient amount of inhibitor, sensitivity was essentially fully restored in both cases.	oxazaphosphorines	95-112	selectin P ligand	Homo sapiens	188-191
3967238-6	1985	Inasmuch as the L1210/CPA cell line was specifically resistant to the oxazaphosphorines, identification of the phenotypic basis for this resistance should serve to identify a potentially important determinant with regard to the basis for the oncotoxic specificity of this group of agents.	oxazaphosphorines	70-87	carboxypeptidase A1, pancreatic	Mus musculus	22-25
29693342-0	2016	Urinary kidney injury molecule-1 (KIM-1) excretion in rats with experimental cystitis induced by oxazaphosphorines.	oxazaphosphorines	97-114	hepatitis A virus cellular receptor 1	Rattus norvegicus	34-39
24677340-9	2014	Thus, CB29 is a novel small molecule inhibitor of ALDH3A1, which might be useful as a chemical tool to delineate the role of ALDH3A1 in numerous metabolic pathways, including sensitizing ALDH3A1-positive cancer cells to oxazaphosphorines.	oxazaphosphorines	220-237	aldehyde dehydrogenase 3 family member A1	Homo sapiens	50-57
24349963-8	2012	Here, we review current advances regarding the influence of xenobiotic receptors, particularly, the constitutive androstane receptor, the pregnane X receptor and the aryl hydrocarbon receptor, on the bioactivation and detoxification of oxazaphosphorines, with a focus on cyclophosphamide and ifosfamide.	oxazaphosphorines	236-253	nuclear receptor subfamily 1 group I member 2	Homo sapiens	138-157
24349963-8	2012	Here, we review current advances regarding the influence of xenobiotic receptors, particularly, the constitutive androstane receptor, the pregnane X receptor and the aryl hydrocarbon receptor, on the bioactivation and detoxification of oxazaphosphorines, with a focus on cyclophosphamide and ifosfamide.	oxazaphosphorines	236-253	aryl hydrocarbon receptor	Homo sapiens	166-191
16393888-13	2005	The metabolism of oxazaphosphorines is auto-inducible, with the activation of the orphan nuclear receptor pregnane X receptor (PXR) being the major mechanism.	oxazaphosphorines	18-35	nuclear receptor subfamily 1 group I member 2	Homo sapiens	127-130
22206977-14	2012	High ALDH3A1 expression and activity have been correlated with cell proliferation, resistance against aldehydes derived from lipid peroxidation, and resistance against drug toxicity, such as oxazaphosphorines.	oxazaphosphorines	191-208	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	5-12
20405259-0	2010	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).	oxazaphosphorines	15-32	ATP binding cassette subfamily C member 4	Homo sapiens	38-79
20405259-0	2010	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).	oxazaphosphorines	15-32	ATP binding cassette subfamily C member 4	Homo sapiens	81-85
20405259-2	2010	MRP4 could have an influence on the resistance and transport of the two oxazaphosphorines, cyclophosphamide (CP) and ifosfamide (IF).	oxazaphosphorines	72-89	ATP binding cassette subfamily C member 4	Homo sapiens	0-4
20405259-4	2010	HepG2 and HEK293 human kidney cells were also used to investigate the inducing potency of oxazaphosphorines on the MRP4 expression.	oxazaphosphorines	90-107	ATP binding cassette subfamily C member 4	Homo sapiens	115-119
16475710-1	2006	The oxazaphosphorines cyclophosphamide (CP) and ifosfamide (IF) are alkylating agents that require bioactivation via cytochrome (CYP) P450 isoenzymes including CYP2C9 enzymes.	oxazaphosphorines	4-21	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	160-166
22701146-2	2012	This study investigated whether oxazaphosphorines alter the expression of organic cation/carnitine transporter (OCTN2) and antioxidant genes and if so, whether these alterations contribute to CP and IFO-induced cardiotoxicity.	oxazaphosphorines	32-49	solute carrier family 22 member 5	Rattus norvegicus	112-117
22701146-7	2012	Data from this study suggest that: (1) Oxazaphosphorines decreased myocardial carnitine content following the inhibition of OCTN2 mRNA and protein expression in cardiac tissues.	oxazaphosphorines	39-56	solute carrier family 22 member 5	Rattus norvegicus	124-129
16293390-0	2006	Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.	oxazaphosphorines	14-31	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-50
16293390-1	2006	Cancer chemotherapeutic prodrugs, such as the oxazaphosphorines cyclophosphamide and ifosfamide, are metabolized by liver cytochrome P450 enzymes to yield therapeutically active, cytotoxic metabolites.	oxazaphosphorines	46-63	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	133-137
16393888-15	2005	Several drug transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated proteins (MRP1, MRP2, and MRP4) are involved in the active uptake and efflux of parental oxazaphosphorines, their cytotoxic mustards and conjugates in hepatocytes and tumor cells.	oxazaphosphorines	197-214	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	35-67
16393888-15	2005	Several drug transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated proteins (MRP1, MRP2, and MRP4) are involved in the active uptake and efflux of parental oxazaphosphorines, their cytotoxic mustards and conjugates in hepatocytes and tumor cells.	oxazaphosphorines	197-214	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	69-73
16393888-15	2005	Several drug transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated proteins (MRP1, MRP2, and MRP4) are involved in the active uptake and efflux of parental oxazaphosphorines, their cytotoxic mustards and conjugates in hepatocytes and tumor cells.	oxazaphosphorines	197-214	MDM4 regulator of p53	Homo sapiens	118-122
16393888-15	2005	Several drug transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated proteins (MRP1, MRP2, and MRP4) are involved in the active uptake and efflux of parental oxazaphosphorines, their cytotoxic mustards and conjugates in hepatocytes and tumor cells.	oxazaphosphorines	197-214	ATP binding cassette subfamily C member 2	Homo sapiens	124-128
16393888-15	2005	Several drug transporters, such as breast cancer resistance protein (BCRP), multidrug resistance associated proteins (MRP1, MRP2, and MRP4) are involved in the active uptake and efflux of parental oxazaphosphorines, their cytotoxic mustards and conjugates in hepatocytes and tumor cells.	oxazaphosphorines	197-214	ATP binding cassette subfamily C member 4	Homo sapiens	134-138
11320670-3	2001	Preclinical models indicate that cellular sensitivity to cyclophosphamide and other oxazaphosphorines, e.g., ifosfamide, is inversely related to the cellular content of two aldehyde dehydrogenases, viz ALDH1A1 and ALDH3A1, and glutathione.	oxazaphosphorines	84-101	aldehyde dehydrogenase 1 family member A1	Homo sapiens	202-209
14759713-8	2004	In summary, we have demonstrated that tumors of the breast express two out of four members of the CYP2C family, indicating that activation of such prodrugs as oxazaphosphorines may take place intratumorally.	oxazaphosphorines	159-176	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	98-103
12369889-11	2002	Historically, this strategy utilized CYP 2B1 to activate oxazaphosphorines.	oxazaphosphorines	57-74	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
11320670-3	2001	Preclinical models indicate that cellular sensitivity to cyclophosphamide and other oxazaphosphorines, e.g., ifosfamide, is inversely related to the cellular content of two aldehyde dehydrogenases, viz ALDH1A1 and ALDH3A1, and glutathione.	oxazaphosphorines	84-101	aldehyde dehydrogenase 3 family member A1	Homo sapiens	214-221
10469894-2	1999	Each catalyzes the detoxification of the oxazaphosphorines; thus, cellular sensitivity to these agents decreases as cellular levels of ALDH1A1 and/or ALDH3A1 increase.	oxazaphosphorines	41-58	aldehyde dehydrogenase 1 family member A1	Homo sapiens	135-142
11306049-1	2001	ALDH3A1 catalyzes the detoxification of cyclophosphamide, mafosfamide, 4-hydroperoxycyclophosphamide and other oxazaphosphorines.	oxazaphosphorines	111-128	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-7
10856427-2	2000	Since resistance to oxazaphosphorines can be produced in mammalian cells by transfecting them with the gene for human ALDH isozyme 3 (hALDH3), it seems possible that patients receiving therapy for solid tumors with cyclophosphamide might be protected from myelosuppression by their prior transplantation with autologous bone marrow that has been transduced with a retroviral vector causing overexpression of hALDH3.	oxazaphosphorines	20-37	aldehyde dehydrogenase 3 family member A1	Homo sapiens	134-140
10856427-2	2000	Since resistance to oxazaphosphorines can be produced in mammalian cells by transfecting them with the gene for human ALDH isozyme 3 (hALDH3), it seems possible that patients receiving therapy for solid tumors with cyclophosphamide might be protected from myelosuppression by their prior transplantation with autologous bone marrow that has been transduced with a retroviral vector causing overexpression of hALDH3.	oxazaphosphorines	20-37	aldehyde dehydrogenase 3 family member A1	Homo sapiens	408-414
10856427-3	2000	We investigated whether retroviral introduction of hALDH3 into a human leukemia cell line confers resistance to oxazaphosphorines.	oxazaphosphorines	112-129	aldehyde dehydrogenase 3 family member A1	Homo sapiens	51-57
10469894-1	1999	As judged by findings in preclinical models, determinants of cellular sensitivity to cyclophosphamide and other oxazaphosphorines include two cytosolic aldehyde dehydrogenases, viz., ALDH1A1 and ALDH3A1.	oxazaphosphorines	112-129	aldehyde dehydrogenase 1 family member A1	Homo sapiens	183-190
10469894-1	1999	As judged by findings in preclinical models, determinants of cellular sensitivity to cyclophosphamide and other oxazaphosphorines include two cytosolic aldehyde dehydrogenases, viz., ALDH1A1 and ALDH3A1.	oxazaphosphorines	112-129	aldehyde dehydrogenase 3 family member A1	Homo sapiens	195-202
10469894-2	1999	Each catalyzes the detoxification of the oxazaphosphorines; thus, cellular sensitivity to these agents decreases as cellular levels of ALDH1A1 and/or ALDH3A1 increase.	oxazaphosphorines	41-58	aldehyde dehydrogenase 3 family member A1	Homo sapiens	150-157
10905564-1	1999	Oxazaphosphorines are inactive anticancer prodrugs that are bioactivated by hepatic cytochrome P450.	oxazaphosphorines	0-17	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	95-99
10905564-2	1999	Besides hepatic metabolism, there is increasing interest in the possibility of intratumoral activation of oxazaphosphorines by P450.	oxazaphosphorines	106-123	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	127-131
10905564-9	1999	In summary, we have demonstrated that tumors of the CNS express P450, indicating that activation of prodrugs like oxazaphosphorines may take place intratumorally.	oxazaphosphorines	114-131	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	64-68
7834628-0	1995	Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.	oxazaphosphorines	64-81	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	92-108
9776312-0	1998	Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin.	oxazaphosphorines	192-209	ATP binding cassette subfamily C member 1	Homo sapiens	53-56
8654195-1	1995	The cytosolic class aldehyde dehydrogenase (ALDH-3) present in human normal tissues/secretions is apparently much less able to catalyze the oxidation aldophosphamide to carboxyphosphamide than is the ALDH-3 present in human tumor cells/tissues, suggesting that the former may be less able to protect cells from the cytotoxic action of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	oxazaphosphorines	376-393	aldehyde dehydrogenase 3 family member A1	Homo sapiens	44-50
8654195-1	1995	The cytosolic class aldehyde dehydrogenase (ALDH-3) present in human normal tissues/secretions is apparently much less able to catalyze the oxidation aldophosphamide to carboxyphosphamide than is the ALDH-3 present in human tumor cells/tissues, suggesting that the former may be less able to protect cells from the cytotoxic action of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	oxazaphosphorines	376-393	aldehyde dehydrogenase 3 family member A1	Homo sapiens	200-206
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	130-136
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	187-193
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	187-193
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	187-193
8424816-1	1993	Several murine aldehyde dehydrogenases, most notably AHD-2, are known to catalyze the detoxification of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	oxazaphosphorines	145-162	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	53-58